操盘104个账户，“尼古丁第一股”董事长忙两年半反亏739万

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed penalties on Jincheng Pharmaceutical's actual controller Zhao Yeqing for leading a stock manipulation case lasting two and a half years, resulting in his resignation as chairman [3][10][25]. Group 1: Stock Manipulation Case - Zhao Yeqing was fined 1.5 million yuan and banned from the market for four years due to stock manipulation activities [3][10]. - The manipulation involved 104 securities accounts, with over 4 billion yuan in fund transactions, and the accounts participated in trading for 502 out of 595 trading days [6][32]. - Despite the extensive manipulation, the account group incurred a loss of approximately 7.39 million yuan during the operation [7][34]. Group 2: Company Operations and Financials - Jincheng Pharmaceutical, established in 2004 and listed in 2011, specializes in the research, production, and sales of pharmaceutical intermediates and raw materials [15][39]. - The company reported a revenue of 3.373 billion yuan in 2024, a decrease of 4.66% year-on-year, with significant fluctuations in net profit [22][46]. - Recent financial data shows a decline in revenue and net profit, with Q3 2023 revenue at 572 million yuan, down 24.44% year-on-year, and a net loss of 11.81 million yuan [24][48]. Group 3: Management Changes and Future Outlook - Following the penalties, the company emphasized that the operational management would not be affected and plans to elect a new chairman soon [10][25]. - The market is closely watching how the management will adjust in light of the recent events and the ongoing operational pressures [35][49].